p.103 抽出テキスト
318. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report–2013; focus theme: age. J Heart Lung Transplant 2013;32:951–964. https://doi.org/10.1016/j.healun.2013.08.006 319. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1–23. https://doi.org/ 10.1016/j.healun.2015.10.023 320. Bansal A, Akhtar F, Desai S, Velasco-Gonzalez C, Bansal A, Teagle A, et al. Six-month outcomes in postapproval HeartMate3 patients: a single-center US experience. J Card Surg 2022;37:1907–1914. https://doi.org/10.1111/jocs.16452 321. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al. A fully magnetically levitated left ventricular assist device – final report. N Engl J Med 2019; 380:1618–1627. https://doi.org/10.1056/NEJMoa1900486 322. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC Jr, Yuzefpolskaya M, Salerno C, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med 2018;378:1386–1395. https://doi.org/10.1056/NEJMoa1800866 323. Zimpfer D, Gustafsson F, Potapov E, Pya Y, Schmitto J, Berchtold-Herz M, et al. Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. Eur Heart J 2020;41:3801–3809. https://doi.org/10.1093/eurheartj/ehaa639 324. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 2015;34:1495–1504. https://doi.org/10.1016/j.healun.2015.10.003 325. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Randomized evaluation of mechanical assistance for the treatment of Congestive Heart Failure Study Group. Long-term use of a left ventricular assist device for endstage heart failure. N Engl J Med 2001;345:1435–1443. https://doi.org/10.1056/ NEJMoa012175 326. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007;50: 741–747. https://doi.org/10.1016/j.jacc.2007.03.063 327. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241–2251. https://doi.org/10.1056/NEJMoa0909938 328. Goldstein DJ, Naka Y, Horstmanshof D, Ravichandran AK, Schroder J, Ransom J, et al. Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the multicenter study of MagLev technology in patients undergoing mechanical circulatory support therapy with HeartMate 3 (MOMENTUM 3) randomized clinical trial. JAMA Cardiol 2020;5:411–419. https://doi. org/10.1001/jamacardio.2019.5323 329. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, et al. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. Ann Cardiothorac Surg 2018;7:3–11. https://doi.org/10.21037/acs.2017. 09.18 330. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2014;63:1751–1757. https://doi.org/10.1016/j.jacc.2014.01.053 331. Charron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, et al. The Cardiomyopathy registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J 2018;39:1784–1793. https://doi. org/10.1093/eurheartj/ehx819 332. Mizia-Stec K, Caforio ALP, Charron P, Gimeno JR, Elliott P, Kaski JP, et al. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/ Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Fail 2020;7:3601–3609. https://doi.org/ 10.1002/ehf2.12854 333. Gimeno JR, Elliott PM, Tavazzi L, Tendera M, Kaski JP, Laroche C, et al. Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. Eur Heart J Qual Care Clin Outcomes 2021;7:134–142. https://doi.org/10.1093/ehjqcco/qcaa075 334. Fauchier L, Bisson A, Bodin A, Herbert J, Spiesser P, Pierre B, et al. Ischemic stroke in patients with hypertrophic cardiomyopathy according to presence or absence of atrial fibrillation. Stroke 2022;53:497–504. https://doi.org/10.1161/STROKEAHA.121. 034213 335. Buckley BJR, Harrison SL, Gupta D, Fazio-Eynullayeva E, Underhill P, Lip GYH. Atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real-world data. J Am Heart Assoc 2021;10:e021970. https://doi.org/10.1161/JAHA. 121.021970 336. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 373–498. https://doi.org/10.1093/eurheartj/ehaa612 337. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017;14:627–628. https://doi.org/10.1038/nrcardio.2017.153 338. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) pathway. Am J Med 2018;131:1359–1366.e6. https:// doi.org/10.1016/j.amjmed.2018.06.012 339. Yoon M, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. Thromb Haemost 2019;119:1695–1703. https://doi.org/10.1055/s-0039- 1693516 340. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GYH. ABC (Atrial Fibrillation Better Care) pathway and healthcare costs in atrial fibrillation: the ATHERO-AF study. Am J Med 2019;132:856–861. https://doi.org/10.1016/j.amjmed.2019.01.003 341. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (Atrial Fibrillation Better Care) pathway in the ATHERO-AF study cohort. Mayo Clin Proc 2019;94:1261–1267. https://doi.org/10.1016/j.mayocp.2018.10.022 342. Proietti M, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace 2021;23:174–183. https://doi. org/10.1093/europace/euaa274 343. Pastori D, Menichelli D, Violi F, Pignatelli P, Lip GYH; ATHERO-AF study group. The Atrial Fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. Eur J Intern Med 2021; 85:80–85. https://doi.org/10.1016/j.ejim.2020.12.011 344. Stevens D, Harrison SL, Kolamunnage-Dona R, Lip GYH, Lane DA. The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. Europace 2021;23:1511–1527. https://doi.org/10.1093/europace/euab092 345. Yao Y, Guo Y, Lip GYH; mAF-App II Trial investigators. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial. JAMA Netw Open 2021;4:e2140071. https://doi.org/10.1001/jamanetworkopen.2021. 40071 346. Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in patients with atrial fibrillation: impact on clinical outcomes–a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022;122:406–414. https://doi.org/10.1055/a-1515-9630 347. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987–2996. https://doi.org/10.1093/eurheartj/ehx739 348. Wang YF, Jiang C, He L, Du X, Sang CH, Long DY, et al. Integrated care of atrial fibrillation using the ABC (Atrial fibrillation Better Care) pathway improves clinical outcomes in Chinese population: an analysis from the Chinese atrial fibrillation registry. Front Cardiovasc Med 2021;8:762245. https://doi.org/10.3389/fcvm.2021.762245 349. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the ABC (Atrial fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc 2020;9:e014932. https://doi.org/10.1161/JAHA.119.014932 350. Gumprecht J, Domek M, Proietti M, Li YG, Asaad N, Rashed W, et al. Compliance of atrial fibrillation treatment with the Atrial fibrillation Better Care (ABC) pathway improves the clinical outcomes in the Middle East population: a report from the Gulf Survey of Atrial Fibrillation Events (SAFE) registry. J Clin Med 2020;9:1286. https:// doi.org/10.3390/jcm9051286 351. Proietti M, Vitolo M, Lip GYH. Integrated care and outcomes in patients with atrial fibrillation and comorbidities. Eur J Clin Invest 2021;51:e13498. https://doi.org/10.1111/ eci.13498 352. Rivera-Caravaca JM, Roldan V, Martinez-Montesinos L, Vicente V, Lip GYH, Marin F. The Atrial Fibrillation Better Care (ABC) pathway and clinical outcomes in patients with atrial fibrillation: the prospective Murcia AF Project Phase II Cohort. J Gen Intern Med 2023;38:315–323. https://doi.org/10.1007/s11606-022-07567-5 353. Vitolo M, Proietti M, Malavasi VL, Bonini N, Romiti GF, Imberti JF, et al. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: a report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry. Eur J Intern Med 2022;105: 54–62. https://doi.org/10.1016/j.ejim.2022.08.004 354. Patel SM, Palazzolo MG, Murphy SA, Antman EM, Braunwald E, Lanz HJ, et al. Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. Europace 2022;24:1730–1738. https://doi.org/10.1093/europace/euac082 ESC Guidelines 3605 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026